Collagenase Clostridium histolyticum for Dupuytren’s contracture
- Aust Prescr 2014;37:28-35
- 1 February 2014
- DOI: 10.18773/austprescr.2014.013
Approved indication: Dupuytren’s contracture
vials containing 0.9 mg lyophilised powder for reconstitution
Australian Medicines Handbook Appendix A
Dupuytren's contracture is characterised by overproduction and deposition of fibroblasts in the hand. Longitudinal collagen cords form which cause flexion contractures. The ring finger and small finger are most commonly affected and cause considerable disability. Standard treatment is surgery to remove or release the cord, but recurrence occurs in about half of cases.
This product contains two collagenases (AUX-I and AUX-II), produced by the bacterium Clostridium histolyticum. These enzymes hydrolyse collagen and are used to dissolve the collagen cords.
Two placebo-controlled randomised trials – CORD I1 and CORD II2 – assessed the efficacy of collagenase Clostridium histolyticum in adults with Dupuytren's contracture. Patients had at least one finger contracture (with a palpable cord) of 20–100 degrees in a metacarpophalangeal joint or 20–80 degrees in a proximal interphalangeal joint. Approximately 40–50% of enrolled patients had previously had surgery for contractures. Collagenase Clostridium histolyticum 0.58 mg or placebo was injected into the affected cord. The volume of the injection depended on the joint being injected. If needed, the hand was manipulated the next day to facilitate cord disruption. In CORD I, patients were allowed up to three injections given monthly, whereas in CORD II, patients could have a maximum of eight injections over 12 months. Finger contracture was measured four weeks after an injection.
|CORD I trial||CORD II trial|
|Number of patients
|Proportion of patients with reduced contracture (to 5 degrees
or less) 4 weeks after last collagenase injection
In the phase III trials, recurrence rates of contracture (to at least 20 degrees) in joints that had been successfully treated with collagenase were 3.3% (28 of 838 joints) after 12 months and 42% after four years.
Injection-site reactions to collagenase were the most common events and included haemorrhage (38.2% of patients), pain (34.9%), swelling (24.5%) and tenderness (24.1%). Other common adverse events were peripheral oedema (73.5%), contusion (55%), ecchymosis (20.5%) and lymphadenopathy (13.3%).
Most patients developed antibodies to collagenase and 15% had pruritus at the injection site. Anaphylaxis is a risk with this product.
Some patients developed serious injuries to the hand as result of the injection. These included tendon rupture, ligament injury and a complex regional pain syndrome. Patients should be warned to contact their doctor if they are unable to bend their finger after the swelling goes down.
As ecchymosis and haemorrhage were common, this drug should be used with caution in patients with a bleeding disorder or those taking anticoagulants. Except low-dose aspirin, anticoagulants should not be given up to seven days before treatment. Tetracyclines have been shown to inhibit collagen degradation and should be avoided up to 14 days before a collagenase injection.
Although collagenase is undetectable in plasma following an injection into the hand, it is a category B1 pregnancy drug and its use should be postponed until after pregnancy. Caution is urged during breastfeeding.
Collagenase injections provide a convenient option for people with Dupuytren's contracture who cannot have surgery. Approximately half of patients will benefit but complications can occur and treatment has a high relapse rate. Special training is required before a doctor can administer this product.
The Transparency Score () is explained in New drugs: transparency', Vol 37 No 1, Aust Prescr 2014;37:27.